BDRX (BDRX) Stock Price & Analysis
BDRX (BDRX) fell 4.91% to USD 3.1 as of June 10, 2026 at 02:00 UTC, according to Nexqual real-time market data.
BDRX last closed at USD 3.26; the session ranged USD 3.1–3.26 on volume of 15,792 shares. Market capitalization is $2.31M, with a 52-week range of USD 2.86–66.5 (NCM). Source: Nexqual, June 10, 2026 at 02:00 UTC.
Key Statistics (as of June 10, 2026 at 02:00 UTC)
| Price | USD 3.1 |
|---|---|
| Change | ▼ 4.91% (down) |
| Previous Close | USD 3.26 |
| Open | USD 3.26 |
| Day Range | USD 3.1 – 3.26 |
| 52-Week Range | USD 2.86 – 66.5 |
| Volume | 15,792 shares |
| Market Cap | $2.31M |
| Exchange | NCM |
Technical Analysis (BDRX)
Nexqual's technical model rates BDRX "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:00 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.96 (neutral) |
| vs SMA50 | Below (USD 3.49) |
| MACD | -0.09 (negative) |
Analyst Ratings (BDRX)
Wall Street analysts rate BDRX "None" based on 1 analysts, with a mean price target of USD 35.5 (range USD 35.5–35.5), per Nexqual as of June 10, 2026 at 02:00 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 35.5 |
| High Target | USD 35.5 |
| Low Target | USD 35.5 |
| Buy / Hold / Sell | 0 / 0 / 0 |
Earnings (BDRX)
Source: Nexqual, June 10, 2026 at 02:00 UTC.
Financials & Fundamentals (BDRX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -64.72% |
| Debt / Equity | 0.54 |
| Current Ratio | 2.03 |
| Total Cash | $8.53M |
| Total Debt | $61,000 |
| Free Cash Flow | $-1.00M |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
Financial Health Score (BDRX)
Nexqual rates BDRX's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:00 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $9M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$6M |
| Efficiency | Critical — ROE -65%, ROA -32.8% |
Ownership (BDRX)
| Insider Ownership | +0.07% |
|---|---|
| Institutional Ownership | +10.35% |
| Shares Outstanding | 746,114 |
| Float | 594,057 |
| Short % of Float | +1.36% |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
Leadership (BDRX)
BDRX is led by Stephen Anthony Stamp (age 64), CEO & Director, per Nexqual as of June 10, 2026 at 02:00 UTC.
| CEO & Director | Stephen Anthony Stamp (age 64) |
|---|---|
| Company Secretary, CFO & Director | Fiona Mary Powell (age 57) |
| Vice President of Technology | Daniel Palmer |
| Vice President of Clinical Operations | Noreen Bhatti |
Major Backers & Investors (BDRX)
Notable institutional backers of BDRX include Sabby Management, LLC, Armistice Capital, LLC, Gamma Investing LLC, according to Nexqual as of June 10, 2026 at 02:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sabby Management, LLC | 6.9% |
| Armistice Capital, LLC | 2.61% |
| Gamma Investing LLC | 0.37% |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FRGT | Freight Technologies, Inc. | USD 4.5 | ▲ 6.64% |
| TNON | Tenon Medical, Inc. | USD 0.62 | ▲ 2.12% |
| SPRC | SciSparc Ltd. | USD 9.31 | ▼ 18.62% |
| TVGN | Tevogen Bio Holdings Inc. | USD 10.75 | ▲ 2.67% |
| INBS | Intelligent Bio Solutions Inc. | USD 2.42 | ▼ 1.22% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:00 UTC. This page is informational and not investment advice.